Previous Page Next Page

Efficacy (paediatrics)

Data from the phase 1/2 SCOUT trial in paediatric patients and adolescents/young adults with advanced solid or primary CNS tumours were analysed separately and included patients with and without identified NTRK gene fusions [1]. The objective response rate was 93% (14/15) in evaluable patients with cancers with TRK fusion cancer, compared with 0% (0/7) without TRK fusion cancer. Larotrectinib was detectable in the cerebrospinal fluid (CSF) of two patients that underwent standard-of-care sampling with CSF to plasma concentrations of 28% via Ommaya and 123% via lumbar puncture.

Reference

  1. Laetsch TW, DuBois SG, Mascarenhas L et al. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. Lancet Oncol 2018; 19: 705-714.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings